Mental retardation and cardiovascular malformations in *NF1* microdeleted patients point to candidate genes in 17q11.2

*M Venturin, *P Guarnieri, F Natacci, M Stabile, R Tenconi, M Clementi, C Hernandez, P Thompson, M Upadhyaya, L Larizza, P Riva

J Med Genet 2004;41:35–41. doi: 10.1136/jmg.2003.014761

Neurofibromatosis type 1 (*NF1* [MIM 162200]) is a common autosomal dominant disorder that affects 1/3500 individuals and is caused by deletion or point mutations of *NF1*, a tumour suppressor gene mapping to 17q11.2. Its main features include café au lait spots, axillary and inguinal freckling, iris Lisch nodules, neurofibromas, and an increased risk of benign and malignant tumours, particularly optic glioma, neurofibrosarcoma, malignant peripheral nerve sheath tumours (MPNSTs),¹ and childhood myeloid leukaemia.²

Over 70% of *NF1* germline mutations cause truncation or loss of the encoded protein.

Approximately 5–20% of all *NF1* patients carry a heterozygous deletion of usually 1.5 Mb involving the *NF1* gene and contiguous genes lying in its flanking regions,^{3–4} which is caused by unequal homologous recombination of *NF1* repeats (REPs).⁵ Known as the “*NF1* microdeletion syndrome,” this condition is often characterised by a more severe phenotype than is observed in the general *NF1* group. In particular, *NF1* microdeleted patients often show variable facial dysmorphisms, mental retardation, developmental delay, and an excessive number of neurofibromas for age.^{3–6–12} The severe phenotype of microdeleted patients may be explained by variations in the expression of the genes involved in the rearrangement, which may be caused by different mechanisms, such as gene interruptions, position effects, and decreased gene dosages.

Although *NF1* microdeleted patients generally have different characteristics from those of classic *NF1* patients, it remains difficult to foresee the presence of the deletion at an individual level on the basis of clinical observations. Various studies have reported the clinical characterisation of *NF1* deleted patients and the precise extent of the deletion has been characterised in a subset.^{3–5, 13–14} However, no study comparing the incidence of specific clinical signs in *NF1* deleted and classical *NF1* patients has yet been published. The only published comparative study concerned a single clinical sign (the development of an MPNST), for which a correlation between *NF1* microdeletion and a high risk for this tumour was observed.¹

Our aims in the present study were, first, to verify whether the incidence of specific clinical signs is different in *NF1* microdeleted and general *NF1* patients; and second, to indicate possible correlations between the onset of distinct clinical features and the haploinsufficiency of specific genes involved in the deletions. We considered the extra-*NF1* clinical signs shown by a sample of 92 microdeleted patients (evaluated in this study or described in published reports), and estimated their incidence in comparison with the *NF1* patient group as a whole.

Key points

- *NF1* microdeletion syndrome is determined by haploinsufficiency of the *NF1* gene and its flanking regions; *NF1* microdeleted patients show a more severe phenotype than observed in classical *NF1* patients.
- The aim of this study was to verify the presence of specific clinical signs of *NF1* microdeletion, by combining clinical and genetic evidence from 92 deleted patients, 14 newly characterised and 78 already published.
- Statistical analysis, done by comparing the frequency of 10 clinical signs between *NF1* microdeleted patients and the whole *NF1* population, showed that the most common extra-*NF1* clinical signs in microdeleted patients were learning disability, cardiovascular malformations, and dysmorphisms.
- Using bioinformatic tools, the deletion gene content of 44 genetically and clinically characterised patients was established. It is proposed that haploinsufficiency of *OMG* and/or *CDK5R1* genes may be implicated in learning disability. In relation to cardiovascular malformations, only *JJAZ1* and *CENTA2* can be considered as plausible candidate genes.
- When present in an *NF1* patient, dysmorphisms, cardiac anomalies, and learning disability are signs indicating *NF1* microdeletion.

METHODS

Patients

In order to generate a database that was as comprehensive as possible, we data-mined the NCBI Entrez Pubmed¹⁵ and Med Miner repository¹⁶ and retrieved all the individually reported cases of patients affected by the *NF1* microdeletion syndrome whose clinical phenotype was also described.

Signs included among the diagnostic criteria for *NF1* were excluded (with the exception of plexiform neurofibroma), as were minor sporadically present signs for which no incidence figures were available.

Abbreviations: DSM-IV, *Diagnostic and Statistical Manual of Mental Diseases*, fourth edition; FISH, fluorescent in situ hybridisation; MPNST, malignant peripheral nerve sheath tumour; *NF1*, neurofibromatosis type 1

This selection led to a total of 21 papers describing individually reported cases for a total of 78 patients. We excluded seven well characterised patients carrying mosaic deletions from both published reports and the newly characterised cohort.

The references of the extracted articles are 3–14 and 17–25.

Among the 78 patients described in published reports, seven were familial microdeleted patients and in two cases the parent showed a mosaic condition. The remaining apparently sporadic patients can be considered founder deletion carriers, although we cannot exclude low grade or tissue specific mosaicism in the asymptomatic parents. Conversely the 14 new *NF1* deleted patients were recruited by means of loss of heterozygosity (LOH) studies and characterised by FISH (fluorescent in situ hybridisation) analysis. Extension of FISH to the patients' parents contributing the deletion allowed us to identify a mosaic deletion in parents of cases 65 and 94, and to exclude low grade mosaicism in the remaining cases.

Both the newly described patients and those described in the published reports fulfilled the NIH diagnostic criteria. We classified microdeleted patients as being affected by mental retardation only in those cases where intelligence quotient (IQ) was reported or where an explicit statement of mild to moderate to severe mental retardation was declared by the investigators. When IQ was known, patients were classified as having mild (IQ = 50–70) or moderate to severe mental retardation (IQ < 50) according to the DSM-IV criteria.

With respect to cardiovascular malformations, we referred to large surveys of *NF1* patients investigated by conventional methods for the diagnosis of cardiovascular malformations (auscultation, radiography, electrocardiography, echocardiography), as these methods were applied to the *NF1* microdeleted patients described.

The data on the percentages of each clinical sign in classic *NF1* patients were drawn from published reviews.^{2, 26–29} These reference percentages may also include patients carrying the *NF1* deletion, the relative percentage of which is estimated to be 5–20%.⁴

Database construction

The published reports and the recruited patients allowed us to build a common data structure in which to tabulate the information. For each patient, we added any new clinical sign that had not been included previously, thus obtaining a relational database with 103 fields.

The presence of a specific sign was attributed only when it was explicitly reported and formalised in binary fashion (that is, present or not present). When a field could not be completed because of lack of information or an ambiguous interpretation, it was defined as null and was not counted.

Statistical analysis

The analysed features were studied as discrete variables. As the clinical data concerning each feature were not available for all the patients, the total number of patients for whom the data were applicable is given in each data entry. The frequency of each sign was calculated as the ratio between the evaluable patients and the affected patients, and the two patient populations were statistically compared using the χ^2 test in 2×2 tables with one degree of freedom and a 0.1% error probability (confidence range 99.9%).

Electronic database information

The proximal and distal boundaries of each kind of deletion were defined, and the deletion specific gene content was identified, using the integrated maps available on NCBI (<http://www.ncbi.nlm.nih.gov/genome/seq/>) and UCSC (<http://genome.cse.ucsc.edu/>).

Information concerning the expression patterns, the presence of specific functional domains in the protein products and their putative cellular role, and the existence of orthologous genes in model organisms was obtained from the following internet pages: LocusLink (<http://www.ncbi.nlm.nih.gov/LocusLink/>), Human unidentified gene-encoded large proteins analyzed by Kazusa cDNA Project (HUGE) (<http://www.kazusa.or.jp/huge/>), SAGE (<http://www.ncbi.nlm.nih.gov/SAGE/>), BODYMAP (<http://bodymap.ims.u-tokyo.ac.jp/>), NCI60 cancer microarray project (<http://genome-www.stanford.edu/nci60/>) and, for the homologous murine sequences, mouse genome informatics (<http://www.informatics.jax.org/>).

The sequence homologies identified in *Mus Musculus* by means of a BLAST search were confirmed using an analysis in MGI and *e! The Mouse Genome Sequencing Consortium Mouse Genome Browser*, in which the orthologous regions have been mapped. The rat data were drawn from *Rat genome data* (<http://www.informatics.jax.org/rat/>).

The functional domain analysis for the proteins encoded by the studied genes was undertaken using the tools and links in the expert protein analysis system (EXPASY) molecular biology server (<http://www.expasy.ch/>).

RESULTS

Clinical evaluation of *NF1* patients

In order to verify the presence and incidence of specific clinical signs in *NF1* microdeleted patients in comparison with those with classic neurofibromatosis 1, we considered a sample of 92 microdeleted patients (14 novel clinical descriptions and 78 from published reports).

Table 1 shows the clinical signs and symptoms on which it was possible to make the comparative analysis. Among the clinical signs found to be more frequent in *NF1* microdeleted patients than in the classic *NF1* patients, there was a significant difference ($p < 0.001$, that is, 99.9%) in the incidence of dysmorphic features, hypertelorism, mental retardation, and cardiovascular malformations (table 1).

When available, we also extracted information on the extent of the deletion when molecular cytogenetic characterisation had been undertaken. Of the 92 microdeleted patients, 44 underwent microsatellite or FISH and long range polymerase chain reaction (PCR) analysis, including 28 for whom the information was retrieved from published reports,^{4, 5, 13, 14} 14 described in the present study, plus two previously reported cases that had been precisely characterised by our group using FISH.³

Table 2 lists the clinical features of the 14 previously unreported microdeleted patients, including those who differed from the *NF1* classical phenotype in the statistical analysis. Four patients had short stature or retarded growth, one had macrocephaly, and one was microcephalic. Only one patient had excessive growth. Nine patients had dysmorphisms, only two had mild mental retardation, and three had cardiovascular diseases. Examples of patients with facial dysmorphisms from the newly described microdeleted group are shown in fig 1.

The 44 finely characterised patients were then grouped on the basis of the extent of their deletion to explore possible genotype–phenotype correlations. Thirty seven patients carrying REP deletions made it possible to explore phenotypical variability within a subset having the same deletion: dysmorphic features, mental retardation, and cardiovascular anomalies were present in, respectively, 34 of 37 patients (92%), 12 of 26 (46.1%), and 7 of 37 (19%).

Eight patients with unusual sized deletions (one or both endpoints not falling within the *NF1* REPs) were a further main resource for the genotype–phenotype correlation study of *NF1* patients carrying different deletions. They included

Table 1 Presence of specific clinical signs in 92 NF1 microdeleted patients v NF1 patients according to published reports

Clinical signs	NF1 microdeleted patients			NF1 patients	
	Total evaluable	Total affected	%	%	Discordance* (χ^2 value)
Plexiform neurofibroma	88	25	28	25 to 30	No (0.36 to 0.13)
Macrocephaly	63	20	32	40 to 50	No (1.6 to 6.48)
Facial dysmorphism†	88	69	78	5 to 15	Yes (1065.8 to 264.6)
Hypertelorism	64	27	42	15	Yes (48.60)
Learning disability	63	36	57	4 to 8	Yes (702 to 300.1)
Seizures	56	5	9	3.8 to 6	No (7.11 to 1.5)
Cardiovascular malformations‡	61	11	18	2.1	Yes (120.39)
Deafness	82	2	2	5.3	No (2.05)
Scoliosis	60	9	15	10 to 30	No (2.5 to 7.5)
Pectus excavatum-carinatum	58	10	17	20	No (0.45)

*The discordant values between the two groups of patients and the relative clinical signs are given in bold.

†Including the following signs, each observed in at least one patient: coarse face, flat occiput/brachycephaly, facial asymmetry, prominent forehead, frontal bossing, ptosis, downslanting deep set eyes, eversion of the lateral eyelid, epicanthic folds, strabismus, large nose, prominent nose, high nasal bridge, broad nasal bridge, broad nose, bulbous nasal tip, large ears, low set ears, malar hypoplasia, wide philtrum, prominent philtrum, small mouth, thick lips, micrognathia, small pointed chin, low posterior hairline.

‡Including: atrial septal defect, ventricular septal defect, patent ductus arteriosus, pulmonary stenosis, dilated aortic valve, hypertrophic cardiomyopathy, mitral valve prolapse.

three patients (BL, 106-3, BUD)^{3 5 14 18} carrying large deletions that extended centromerically to REP-P and telomerically to REP-M, all of whom suffered from mental retardation; two (BL and 106-3) also had dysmorphic features, but only BL had hypertelorism. Patients 113-1 and TOP^{5 14} had small deletions where the telomeric endpoint lies within REP-M

but the centromeric endpoint was localised 5' of the *NF1* gene: both showed mental retardation and facial dysmorphisms (including hypertelorism in patient 113-1). Atypical deletions included case 118 (present study)—who suffered from seizures and in whom the telomeric boundary was between *NF1* intron 6 and exon 10b, whereas centromerically

Table 2 Clinical features of the 14 newly described patients carrying NF1 microdeletion characterised by refined fluorescent in situ hybridisation (FISH) analysis

Clinical signs								
Patient	Age (years)	Sex	Deletion type	Growth defects	Dysmorphic	Learning disability	Cardiovascular malformation	Other features
119	4	M	REP	No	No	No	–	
118	5	M	cen-REP	No	No	No	–	Optic glioma, seizures
93	6	M	REP	90th centile, macrocephaly	Yes*	No	HCM	Broad neck, 3 NFs
65	6	M	REP	Height 3rd centile, microcephaly 2nd centile	Yes†	IQ48	VSD (upper part)	Small hands/feet, short fingers
116	6	M	REP	Short stature 10th centile	Yes‡	IQ54	Mitral insufficiency	MCLS, kyphoscoliosis, pectus excavatum, genu valgus, pes planus, umbilical hernia
72	7	M	REP	No	Yes§	IQ50		Small hands/feet, short fingers
76	8	F	REP	No	Yes¶	No	–	–
94	8	F	REP	No	Yes**	No	–	–
75	9	F	REP	No	Yes††	No	–	–
85	11	M	REP	No	No	IQ77	–	MCLS
7	11	M	REP	No	Yes‡‡	Speech impairment	–	MCLS, amblyopia, thalamic hamartoma
82	23	F	REP	Short stature	No	No	–	Hearing impairment, Noonan-like
77	U	F	REP	Overgrowth >97th centile	Yes§§	Speech impairment, LD	–	NFs, required special education, short and broad fingers and toes
78	U	F	REP	–	Yes¶¶	Speech impairment	–	Delayed motor development, short and broad feet, fifth finger clinodactyly

*Hypertelorism, epicanthic folds, low set ears, low posterior hairline.

†Hypertelorism, downslanting eye, strabismus, large and prominent nose with high and broad bridge, bulbous nasal tip, large and low set ears, malar hypoplasia, wide and prominent philtrum, small mouth, small pointed chin.

‡Hypertelorism, long philtrum, broad nose.

§Prominent forehead, hypertelorism, ptosis (O.DX), downslanting eyes; strabismus, large and prominent nose with high and broad bridge and bulbous nasal tip, large and low set ears, wide and prominent philtrum, low posterior hairline.

¶Coarse face, hypertelorism.

**††Epicanthic folds.

‡‡Hypertelorism, broad and wide nasal bridge, broad nasal tip.

§§Simple facial features.

¶¶Epicanthic folds, bulbous nose, narrow high palate, low forehead.

cen-REP, deletion extending centromerically to REP-P; CVM, cardiovascular malformations; F, female; HCM, hypertrophic cardiomyopathy; LD, learning disabilities; M, male; MCLS, multiple café-au-lait spots; NF, neurofibroma; REP, NF1 repeat mediated deletion; U, unknown; VSD, ventricular septal defect.

Figure 1 Facial appearance of three patients with NF1 microdeletions: case 116 at age 6 years (A), case 65 at age 6 (B), and case 72 at age 7 (C). See table 2 for details of the facial dysmorphisms.

it extended beyond REP-P—and case 155-1,⁵ whose deletion ranged from the 5' of the *NF1* gene to a breakpoint region (also shared by BL and 106-3), and who had dysmorphic features and mental retardation.

Deletion gene content analysis in NF1 patients

On the basis of the deletion characterisation of 44 patients (16 analysed in our laboratory and 28 described by other investigators), we identified a critical genomic interval including all but one of the characterised deletions (fig 2)^{5 30}; the only exception was patient BUD, who had a deletion extending beyond the most telomeric *ACCN1* gene (fig 2).¹⁴

The genomic interval comprises 21 genes with a known function, 10 with an unknown function, and 30 with predicted functions supported by mRNA or EST alignments with the genomic contig. The genes with a known function are shown in fig 2.

As dysmorphisms, mental retardation, and cardiovascular malformations were found to be commonly present in the *NF1* microdeleted subgroup in comparison with the *NF1* non-deleted patients, we searched the deleted region for candidate genes that might be involved in producing clinical signs such as mental retardation and

cardiovascular malformations, defined on the basis of the target tissue or organ—that is, the central nervous system and the heart. By combining database screening and published findings concerning gene expression patterns and function, we identified six genes where haplo-insufficiency may be involved in the onset of mental retardation (*SLC6A4*, *OMG*, *RHBDL4*, *ZNF207*, *CDK5R1*, and *ACCN1*), and two possible candidates for cardiovascular malformations (*CEN2A2* and *JJAZ1*). In particular, the oligodendrocyte-myelin glycoprotein (*OMG*) gene, which maps within the REP interval (fig 2), encodes for a protein that has been recently shown to be a potent inhibitor of neurite outgrowth.³¹

The solute carrier family 6 (serotonin neurotransmitter transporter) member 4 gene (*SLC6A4*) (fig 2) maps centromerically to REP-P; its product is a transporter involved in the uptake of the serotonin neurotransmitter by presynaptic neurones or glial cells.³²

The remaining candidate genes for mental retardation are shared by the non-REP deletions extending telomerically to REP-M (fig 2).

A good candidate for mental retardation is the cyclin dependent kinase 5 regulatory subunit 1 gene (*CDK5R1*), which encodes a neurone specific activator of cyclin

Figure 2 Mapping to 17q11.2 region, from *SLC6A4* gene to *ACCN1* gene, of REP and unusual deletions from 44 *NF1* microdeleted patients. All the genes with a known function are shown in the upper line: the candidate genes for mental retardation and cardiovascular malformations are respectively boxed and underlined; the black boxes represent *NF1* REP-P and REP-M. The white, grey, and black circles at each deletion interval indicate absent, mild, and moderate to severe mental retardation, respectively. The white and black squares indicate the absence and presence of cardiovascular malformations. The frequencies of the conditions related to the above clinical signs are also given for the group of patients (n=37) carrying an REP deletion. For the unusually sized deletions, the specific patient codes are indicated on the left.

dependent kinase 5 (*CDK5*) required for the proper development and functioning of the central nervous system.^{33–34} In addition, the neuronal amiloride sensitive cation channel 1 (*ACCNI*), zinc finger protein 207 (*ZNF207*), and rhomboid veinlet-like 4 (*RHBDL4*) genes—which respectively encode a neurone specific member of the degenerin/epithelial sodium channel (*DEG/ENaC*) superfamily, a zinc finger protein, and a protein homologous to the *D melanogaster* transmembrane Rhomboid protein^{35–38}—are all strongly expressed in the central nervous system.

The Joined to *JAZF1* (*JJAZ1*) and centaurin- α 2 (*CENTA2*) genes, which are significantly expressed in the heart and candidates for cardiovascular anomalies, were found to be included in the REP deletion interval (fig 2).

DISCUSSION

In this study we considered the clinical signs not included among the NIH consensus diagnostic criteria in a sample of 92 microdeleted patients, and compared their incidence with that given for classical *NF1* patients. We also established the gene content of 44 deletions of known extent, and sought to identify distinct clinical sign–genotype correlations.

Over the last few years, several papers have reported a more severe phenotype in patients carrying a microdeletion than in those affected by mutational neurofibromatosis,^{1–3–5–8–12} although, as pointed out by Tonsgard *et al.*,¹⁰ phenotype evaluation per se is not predictive of the microdeletion.

By comparing a large sample of *NF1* microdeleted patients with the published data on classical *NF1* patients, we attempted to define the differences in the incidence of the selected clinical signs between the two populations. When selecting the clinical characteristics, we excluded all the signs and symptoms that are diagnostic criteria for *NF1*, in order to identify those that might highlight the candidate genes in *NF1* microdeletion syndrome. One exception to this rule was plexiform neurofibroma, for which we considered the latest emerging correlations between microdeletions and the development of malignancy in the tumour.¹ Conversely, although a high incidence of neurofibromas has been reported in microdeleted patients, we did not include the age dependent sign of neurofibroma development because of the heterogeneity of the sample and the frequent lack of information about neurofibroma onset.

We were aware that we may have underestimated the difference in the incidence of the selected clinical signs between classic *NF1* and *NF1* deleted patients because the more recently identified and characterised patients with deletions are included in the general *NF1* population evaluated in previous published reports.

Dysmorphic features

The results of our study suggest a significantly higher frequency of dysmorphisms, hypertelorisms, mental retardation, and cardiac anomalies in microdeleted patients (table 1). With regard to dysmorphisms, an ascertainment bias needs to be considered because the patients sent for microdeletion analysis are commonly affected by a visibly more severe phenotype which includes dysmorphic traits, whereas these may be present but not reported in non-deleted *NF1* patients. This has also been shown recently in relation to other well known microdeletion syndromes such as William's and Velocardio facial syndromes.³⁹ *NF1* gene haploinsufficiency is probably not the only cause of dysmorphisms, which are likely to involve other genes in the complex pathways regulating the correct development of the body as a whole. It is currently impossible to correlate a single gene to such a complex phenotype.

The only distinctive dysmorphic sign that was possible to compare with non-deleted patients was hypertelorism

(table 1), although it may escape evaluation in the non-deleted patients. It is easily detectable and therefore likely to be reported more often than other signs. We agree with Tonsgard on the difficulty of defining a specific dysmorphic sign for *NF1* microdeletion syndrome,¹⁰ despite the consistent general impression of a coarse and dysmorphic face. For all of these reasons, we believe that no conclusions can be drawn concerning the higher incidence of dysmorphisms in *NF1* deleted patients.

Mental retardation

Another sign that was more represented in *NF1* deleted patients was mental retardation. It is worth noting that *NF1* patients carrying large deletions have an increased frequency of structural brain anomalies revealed by neuroimaging studies, as shown by Korf and coworkers.⁴⁰ As these anomalies are not usually seen in *NF1* patients, it is hypothesised that mental retardation may at least partially reflect abnormal brain development rather than defective brain function caused by neurofibromin haploinsufficiency.⁴⁰ Zhu and coworkers⁴¹ have shown that the cerebral cortex of *NF1*-null mouse embryos develops abnormally, thus suggesting the involvement of neurofibromin in CNS development. *NF1* patients rarely have a severe mental retardation (the incidence is similar to that found in the general population, at 3–5%), but often show a wide range of lesser mental retardation and cognitive defects.^{42–43} The significantly higher incidence of moderate to severe mental retardation in microdeleted patients probably reflects the haploinsufficiency of one or more contiguous genes in addition to *NF1*.

We identified six candidate genes for mental retardation in the deletion intervals, of which *OMG* and *CDK5R1* are particularly interesting because of their known function in CNS development. *CDK5R1* encodes a neurone specific activator of cyclin dependent kinase 5.⁴⁴ *Cdk5r* KO mice have severe cortical lamination defects and suffer from adult mortality and seizures.^{33–34} Moreover, an active CDK5-p35 complex is present in Golgi membranes, and antisense oligonucleotide suppression of *Cdk5* or p35 blocks the formation of membrane vesicles from the Golgi apparatus in young cultured neurones.⁴⁵ These results suggest that Cdk5-p35 plays a role in membrane trafficking during the outgrowth of neuronal processes.

It has recently been shown that *OMG* is a potent inhibitor of neurite outgrowth that acts by binding to the Nogo receptor, a protein associated with myelin.³¹ Interestingly, *OMG* lies within an *NF1* intron, and the fact that its expression pattern overlaps that of *NF1* suggests that the activity of the two genes might be under coordinated control.⁴⁶ The deletion of the entire *NF1* gene (and therefore *OMG*) may deregulate this control mechanism and thus contribute to the mental retardation outcome in microdeleted patients.

We also compared the presence and severity of mental retardation with the different deletion intervals with precisely mapped end points. As summarised in fig 2, 38.6% of the patients carrying an REP deletion have mental retardation, but only 7.7% have moderate to severe mental retardation. On the other hand, all of the four patients with a deletion extending telomerically to the REP-M are affected by moderate or severe mental retardation, which may indicate that haploinsufficiency of one or more genes distally to REP-M, such as *CDK5R1*, plays a critical role in brain function or development, thus accounting for the onset of mental retardation in patients carrying such deletions. The hypothesis that severe mental retardation is indicative of a deletion extending telomerically to REP-M needs to be confirmed by parallel clinical and genetic characterisations of a larger number of microdeleted patients.

Cardiovascular malformations

In relation to cardiovascular involvement, several papers have recently highlighted the presence of cardiac and cardiovascular anomalies in patients with neurofibromatosis; in particular, Friedman *et al* have underlined the recurring cardiovascular anomalies that should be investigated in all patients with a diagnosis of *NF1*.⁴⁷ It has also been reported that neurofibromin plays a role in heart development,⁴⁸ and that *NF1* mutations should be taken into account as a cause of cardiac malformations. Our sample indicates a much higher incidence of cardiac malformations in microdeleted patients, thus suggesting a possible contribution to correct cardiac development of at least one of the other deleted genes contiguous to *NF1*.

All the 11 patients with cardiovascular malformations carry a REP deletion, thus indicating the possible presence within this region of one or more genes involved in the development of the cardiovascular system. Currently, the available functional data concerning the genes included in REP intervals do not allow us to identify genes that are possibly involved in heart development. We did, however, consider *CENTA2*, which encodes a phosphatidylinositol binding protein,⁴⁹ and *JJAZ1*, a zinc finger containing protein,⁵⁰ as candidates because of their high level of expression in heart tissue.

Further in silico and expression studies are in progress to identify genes with a known or unknown function that map in the interval of typical and atypical deletions and may be involved in heart development.

Conclusions

Dysmorphisms, cardiac anomalies, and mental retardation are signs which, when present in an *NF1* patient, should lead to the suspicion of a microdeletion involving the *NF1* and contiguous genes. On the basis of our data, the more severe phenotype is probably caused by the loss of other contiguous genes as well as by *NF1* haploinsufficiency.

It should also be considered that, in addition to the deletion itself, the variation in the level of expression of the genes involved in the rearrangements may also be caused by additional mechanisms, such as gene interruption and the position effect of genes flanking the deletions. Modulation of the overall clinical phenotype associated with specific polymorphisms has been described in Velo cardiofacial syndrome,⁵¹ and additional genetic factors are probably involved in the clinical phenotypic variations observed in patients carrying a similar REP deletion.

As the number of the microdeleted patients carrying REP and non-REP deletions increases, more specific genotype-phenotype correlations can be inferred and may validate the differences we observed in the incidence of specific signs between microdeleted and classic *NF1* patients.

ACKNOWLEDGEMENTS

We thank Dr C Gervasini, Dr F Orzan, and P Colapietro for their contribution to FISH analysis of the newly characterised *NF1* microdeleted patients. This work was supported by a 2002 grant from FIRST to PR and by a 2002 grant from AIRC to LL.

Authors' affiliations

M Venturin, P Guarnieri, L Larizza, P Riva, Department of Biology and Genetics, Medical Faculty, University of Milan, Italy

F Natacci, Medical Genetics Service, Istituti Clinici di Perfezionamento, Milan

M Stabile, Medical Genetics Service, Cardarelli Hospital, Naples, Italy
R Tenconi, M Clementi, Clinical Genetics and Epidemiology Unit, Department of Paediatrics, University of Padua, Italy

C Hernandez, Molecular Genetics Unit, Hospital Ramon y Cajal, Madrid, Spain

P Thompson, M Upadhyaya, Institute of Medical Genetics, University of Wales College of Medicine, Cardiff, UK

*These authors contributed equally to the study

Correspondence to: Professor Paola Riva, Department of Biology and Genetics, Medical Faculty, University of Milan, Italy; paola.riva@unimi.it

Received 22 September 2003

Accepted 2 November 2003

REFERENCES

- 1 De Raedt T, Brems H, Wolkenstein P, Vidaud D, Pilotti S, Perrone F, Mautner V, Frahm S, Sciort R, Legius E. Elevated risk for MPNST in *NF1* microdeletion patients. *Am J Hum Genet* 2003;**72**:1288–92.
- 2 Huson SM, Huges RC. *The neurofibromatosis: a clinical and pathogenetic overview*. London: Chapman and Hall, 1994.
- 3 Riva P, Corrado L, Natacci F, Castorina P, Wu BL, Schneider GH, Clementi M, Tenconi R, Korf BR, Larizza L. *NF1* microdeletion syndrome: refined FISH characterization of sporadic and familial deletions with locus-specific probes. *Am J Hum Genet* 2000;**66**:100–9.
- 4 Jenne DE, Tinschert S, Reimann H, Lasinger W, Thiel G, Hameister H, Kehr-Sawatzki H. Molecular characterization and gene content of breakpoint boundaries in patients with neurofibromatosis type 1 with 17q11.2 microdeletions. *Am J Hum Genet* 2001;**69**:516–27.
- 5 Dorschner MO, Sybert VP, Weaver M, Pletcher BA, Stephens K. *NF1* microdeletion breakpoints are clustered at flanking repetitive sequences. *Hum Mol Genet* 2000;**9**:35–46.
- 6 Kayes LM, Burke W, Riccardi VM, Bennett R, Ehrlich P, Rubenstein A, Stephens K. Deletions spanning the neurofibromatosis 1 gene: identification and phenotype of five patients. *Am J Hum Genet* 1994;**54**:424–36.
- 7 Wu BL, Austin MA, Schneider GH, Boles RG, Korf BR. Deletion of the entire *NF1* gene detected by the FISH: four deletion patients associated with severe manifestations. *Am J Med Genet* 1995;**59**:528–35.
- 8 Leppig KA, Kaplan P, Viskochil D, Weaver M, Ortenberg J, Stephens K. Familial neurofibromatosis 1 microdeletions: cosegregation with distinct facial phenotype and early onset of cutaneous neurofibromatosis. *Am J Med Genet* 1997;**73**:197–204.
- 9 Cnossen MH, van der Est MN, Breuning MH, van Asperen CJ, Breslau-Siderius EJ, van der Ploeg AT, de Goede-Bolder A, van den Ouweland AM, Halley DJ, Niermeijer MF. Deletions spanning the neurofibromatosis type 1 gene: implications for genotype-phenotype correlations in neurofibromatosis type 1? *Hum Mutat* 1997;**9**:458–64.
- 10 Tonsgard JH, Yelavarthi KK, Cushner S, Short MP, Lindgren V. Do *NF1* gene deletions result in a characteristic phenotype? *Am J Med Genet* 1997;**73**:80–6.
- 11 Rasmussen SA, Colman SD, Ho VT, Abernathy CR, Arn PH, Weiss L, Schwartz C, Saul RA, Wallace MR. Constitutional and mosaic large *NF1* gene deletions in neurofibromatosis type 1. *J Med Genet* 1998;**35**:468–71.
- 12 Upadhyaya M, Ruggieri M, Maynard J, Osborn M, Hartog C, Mudd S, Penttinen M, Cordeiro I, Ponder M, Ponder BA, Krawczak M, Cooper DN. Gross deletions of the neurofibromatosis type 1 (*NF1*) gene are predominantly of maternal origin and commonly associated with a learning disability, dysmorphic features and developmental delay. *Hum Genet* 1998;**102**:591–7.
- 13 Lopez Correa C, Brems H, Lazaro C, Marynen P, Legius E. Unequal meiotic crossover: a frequent cause of *NF1* microdeletions. *Am J Hum Genet* 2000;**66**:1969–74.
- 14 Jenne DE, Tinschert S, Stegmann E, Reimann H, Nurnberg P, Horn D, Naumann I, Buske A, Thiel G. A common set of at least 11 functional genes is lost in the majority of *NF1* patients with gross deletions. *Genomics* 2000;**66**:93–7.
- 15 Schuler GD, Epstein JA, Ohkawa H, Kans JA. Entrez: molecular biology database and retrieval system. *Methods Enzymol* 1996;**266**:141–62.
- 16 Tanabe L, Scherf U, Smith LH, Lee JK, Hunter L, Weinstein JN. MedMiner: an Internet text-mining tool for biomedical information, with application to gene expression profiling. *Biotechniques* 1999;**27**:1210–14, 1216–17.
- 17 Upadhyaya M, Roberts SH, Maynard J, Sorour E, Thompson PW, Vaughan M, Wilkie AO, Hughes HE. A cytogenetic deletion, del(17)(q11.22q21.1), in a patient with sporadic neurofibromatosis type 1 (*NF1*) associated with dysmorphism and developmental delay. *J Med Genet* 1996;**33**:148–52.
- 18 Riva P, Castorina P, Manoukian S, Dalpra L, Doneda L, Marini G, den Dunnen J, Larizza L. Characterization of a cytogenetic 17q11.2 deletion in an *NF1* patient with a contiguous gene syndrome. *Hum Genet* 1996;**98**:646–50.
- 19 Leppig KA, Viskochil D, Neil S, Rubenstein A, Johnson VP, Zhu XL, Brothman AR, Stephens K. The detection of contiguous gene deletions at the neurofibromatosis 1 locus with fluorescence in situ hybridization. *Cytogenet Cell Genet* 1996;**72**:95–8.
- 20 Colley A, Donnai D, Evans DG. Neurofibromatosis/Noonan phenotype: a variable feature of type 1 neurofibromatosis. *Clin Genet* 1996;**49**:59–64.
- 21 Ainsworth PJ, Chakraborty PK, Weksberg R. Example of somatic mosaicism in a series of de novo neurofibromatosis type 1 cases due to a maternally derived deletion. *Hum Mutat* 1997;**9**:452–7.
- 22 Valero MC, Pascual-Castroviejo I, Velasco E, Moreno F, Hernandez-Chico C. Identification of de novo deletions at the *NF1* gene: no preferential paternal origin and phenotypic analysis of patients. *Hum Genet* 1997;**99**:720–6.
- 23 Wu BL, Schneider GH, Korf BR. Deletion of the entire *NF1* gene causing distinct manifestations in a family. *Am J Med Genet* 1997;**69**:98–101.

- 24 **Lopez Correa C**, Brems H, Lazaro C, Estivill X, Clementi M, Mason S, Rutkowski JL, Marynen P, Legius E. Molecular studies in 20 submicroscopic neurofibromatosis type 1 gene deletions. *Hum Mutat* 1999;**14**:387-93.
- 25 **Lopez-Correa C**, Dorschner M, Brems H, Lazaro C, Clementi M, Upadhyaya M, Dooijes D, Moog U, Kehr-Sawatzki H, Rutkowski JL, Fryns JP, Marynen P, Stephens K, Legius E. Recombination hotspot in *NF1* microdeletion patients. *Hum Mol Genet* 2001;**10**:1387-92.
- 26 **Friedman JM**, Birch PH. Type 1 Neurofibromatosis: a descriptive analysis of the disorder in 1728 patients. *Am J Med Genet* 1997;**70**:138-43.
- 27 **Ruggieri M**. The different forms of neurofibromatosis. *Childs Nerv Syst* 1999;**15**:295-308.
- 28 **North K**. Neurofibromatosis type 1. *Am J Med Genet* 2000;**97**:119-27.
- 29 **Vivarelli R**, Grosso S, Calabrese F, Farnetani M, Di Bartolo R, Morgese G, Balestri P. Epilepsy in neurofibromatosis 1. *J Child Neurol* 2003;**18**:338-42.
- 30 **Van Roy N**, Vandesompele J, Berx G, Staes K, Van Gele M, De Smet E, De Paepe A, Laureys G, van der Drift P, Versteeg R, Van Roy F, Speleman F. Localization of the 17q breakpoint of a constitutional 1;17 translocation in a patient with neuroblastoma within a 25-kb segment located between the *ACCN1* and *TLK2* genes and near the distal breakpoints of two microdeletions in neurofibromatosis type 1 patients. *Genes Chromosomes Cancer* 2002;**35**:113-20.
- 31 **Wang KC**, Koprivica V, Kim JA, Sivasankaran R, Guo Y, Neve RL, He Z. Oligodendrocyte-myelin glycoprotein is a Nogo receptor ligand that inhibits neurite outgrowth. *Nature* 2002;**417**:941-4.
- 32 **Lesch KP**, Wolozin BL, Estler HC, Murphy DL, Riederer P. Isolation of a cDNA encoding the human brain serotonin transporter. *J Neural Transm Gen Sect* 1993;**91**:67-72.
- 33 **Chae T**, Kwon YT, Bronson R, Dikkes P, Li E, Tsai LH. Mice lacking p35, a neuronal specific activator of Cdk5, displays cortical lamination defects, seizures, and adult lethality. *Neuron* 1997;**18**:29-42.
- 34 **Kwon YT**, Tsai LH. A novel disruption of cortical development in p35(-/-) mice distinct from reeler. *J Comp Neurol* 1998;**395**:510-22.
- 35 **Garcia-Anoveros J**, Derfler B, Neville-Golden J, Hyman BT, Corey DP. BNaC1 and BNaC2 constitute a new family of human neuronal sodium channels related to degenerins and epithelial sodium channels. *Proc Natl Acad Sci USA* 1997;**94**:1459-64.
- 36 **Duggan A**, Garcia-Anoveros J, Corey DP. The PDZ domain protein *PICK1* and the sodium channel BNaC1 interact and localize at mechanosensory terminals of dorsal root ganglion neurons and dendrites of central neurons. *J Biol Chem* 2002;**277**:5203-8.
- 37 **Taguchi E**, Muramatsu H, Fan QW, Kurosawa N, Sobue G, Muramatsu T. Zep: a novel zinc finger protein containing a large proline-rich domain. *J Biochem* 1998;**124**:1220-8.
- 38 **Jaszai J**, Brand M. Cloning and expression of Ventrhold, a novel vertebrate homologue of the *Drosophila* EGF pathway gene rhomboid. *Mech Dev* 2002;**113**:73-7.
- 39 **McDermid HE**, Morrow BE. Genomic disorders on 22q11. *Am J Hum Genet* 2002;**70**:1077-88.
- 40 **Korf BR**, Schneider G, Poussaint TY. Structural anomalies revealed by neuroimaging studies in the brains of patients with neurofibromatosis type 1 and large deletions. *Genet Med* 1999;**1**:136-40.
- 41 **Zhu Y**, Romero MI, Ghosh P, Ye Z, Charnay P, Rushing EJ, Marth JD, Parada LF. Ablation of *NF1* function in neurons induces abnormal development of cerebral cortex and reactive gliosis in the brain. *Genes Dev* 2001;**15**:859-76.
- 42 **Costa RM**, Silva AJ. Molecular and cellular mechanisms underlying the cognitive deficits associated with neurofibromatosis 1 [review]. *J Child Neurol* 2002;**17**:592-601, discussion 602-4, 646-51.
- 43 **Gutmann DH**. Neurofibromin in the brain [review]. *J Child Neurol* 2002;**17**:592-601, discussion 602-4, 646-51.
- 44 **Lew J**, Huang QQ, Qi Z, Winkler RJ. A brain-specific activator of cyclin-dependent kinase 5. *Nature* 1994;**371**:423-6.
- 45 **Paglini G**, Peris L, Diez-Guerra J, Quiroga S, Caceres A. The Cdk5-p35 kinase associates with the Golgi apparatus and regulates membrane traffic. *EMBO Rep* 2001;**2**:1139-44, Epub 2001 Nov 21. Erratum in: *EMBO Rep* 2002;**3**:286.
- 46 **Habib AA**, Marton LS, Allwardt B, Gulcher JR, Mikol DD, Hognason T, Chattopadhyay N, Stefansson K. Expression of the oligodendrocyte-myelin glycoprotein by neurons in the mouse central nervous system. *J Neurochem* 1998;**70**:1704-11.
- 47 **Friedman JM**, Arbiser J, Epstein JA, Gutmann DH, Huot SJ, Lin AE, McManus B, Korf BR. Cardiovascular disease in neurofibromatosis 1: report of the *NF1* Cardiovascular Task Force. *Genet Med* 2002;**4**:105-11.
- 48 **Gitler AD**, Zhu Y, Ismat FA, Lu MM, Yamauchi Y, Parada LF, Epstein JA. *NF1* has an essential role in endothelial cells. *Nat Genet* 2003;**33**:75-9.
- 49 **Whitley P**, Gibbard AM, Koumanov F, Oldfield S, Kilgour EE, Prestwich GD, Holman GD. Identification of centaurin- α 2: a phosphatidylinositol-binding protein present in fat, heart and skeletal muscle. *Eur J Cell Biol* 2002;**81**:222-30.
- 50 **Jenne DE**, Tinschert S, Dorschner MO, Hameister H, Stephens K, Kehr-Sawatzki H. Complete physical map and gene content of the human *NF1* tumor suppressor region in human and mouse. *Genes Chromosomes Cancer* 2003;**37**:111-20.
- 51 **Stalmans I**, Lambrechts D, De Smet F, Jansen S, Wang J, Maity S, Kneer P, von der Ohe M, Swillen A, Maes C, Gewillig M, Molin DGM, 20 others. VEGF: a modifier of the del22q11 (DiGeorge) syndrome? *Nat Med* 2003;**9**:173-82.

ECHO

Severe infantile hyperkalaemic periodic paralysis and paramyotonia congenita: broadening the clinical spectrum associated with the T704M mutation in *SCN4A*

F Brancati, E M Valente, N P Davies, A Sarkozy, M G Sweeney, M LoMonaco, A Pizzuti, M G Hanna, B Dallapiccola

Please visit the Journal of Medical Genetics website [www.jmedgenet.com] for a link to the full text of this article.

An Italian kindred is described with nine individuals affected by hyperkalaemic periodic paralysis associated with paramyotonia congenita (hyperPP/PMC). Periodic paralysis was particularly severe, with several episodes a day lasting for hours. The onset of episodes was unusually early, beginning in the first year of life and persisting into adult life. The paralytic episodes were refractory to treatment. Patients described minimal paramyotonia, mainly of the eyelids and hands. All affected family members carried the threonine to methionine substitution at codon 704 (T704M) in exon 13 of the skeletal muscle voltage gated sodium channel gene (*SCN4A*). The association between T704M and the hyperPP/PMC phenotype has been only recently revealed. Nevertheless, such a severe phenotype has never been reported so far in families with either hyperPP or hyperPP/PMC. These data further broaden the clinical spectrum of T704M and support the evidence that this mutation is a common cause of hyperPP/PMC.

▲ *Journal of Neurology, Neurosurgery, and Psychiatry* 2003;**74**:1339-1341.

LETTER TO JMG

Loci for primary ciliary dyskinesia map to chromosome 16p12.1-12.2 and 15q13.1-15.1 in Faroe Islands and Israeli Druze genetic isolates

D Jeganathan*, R Chodhari*, M Meeks†, O Færoe, D Smyth, K Nielsen, I Amirav, A S Luder, H Bisgaard, R M Gardiner, E M K Chung, H M Mitchison

J Med Genet 2004;41:233–240. doi: 10.1136/jmg.2003.014084

PPrimary ciliary dyskinesia (PCD; Immotile cilia syndrome; OMIM 242650) is an autosomal recessive disorder resulting from dysmotility of cilia and sperm flagella.¹ Cilia and flagella function either to create circulation of fluid over a stationary cell surface or to propel a cell through fluid.^{2,3} These related structures are highly complex organelles composed of over 200 different polypeptides.^{4,5} The core or axoneme of cilia and flagella comprises a bundle of microtubules and many associated proteins. The microtubules are formed from α and β tubulin protofilaments and are arranged in a well recognised '9+2' pattern: nine peripheral microtubule doublets in a ring connected around a central pair of microtubules by radial spoke proteins. The peripheral microtubules have dynein motor proteins attached and are connected with each other by nexin links.^{6–8}

In human beings, ciliated epithelium can be found lining the respiratory tract, including the sinuses and middle ear, the brain ependyma, the female oviduct, and the male vas deferens. Cilia in the respiratory tract play an important part in airway clearance of respiratory secretions. In primary ciliary dyskinesia, impaired mucociliary clearance causes recurrent respiratory tract infections including chronic otitis media, rhinitis, and sinusitis, often leading to permanent lung damage (bronchiectasis).⁹ Patients are also often subfertile due to sperm tail immotility and immotile oviduct cilia. About half of the patients have defects of laterality, usually complete mirror-image reversal of the left-right axis (situs inversus) and this association is known as Kartagener syndrome (OMIM 244400). The defects in left-right axis determination associated with primary ciliary dyskinesia are proposed to result from dysfunction of the embryonic node monocilia during development.^{10–12}

Primary ciliary dyskinesia has an incidence of 1 in 20 000 with enrichment in certain populations.^{9,13} Diagnosis is made on brushings or biopsy of nasal epithelium by demonstration of abnormal ciliary beating, and by demonstration of ultrastructural defects of cilia by electron microscopy.^{14,15} Primary ciliary dyskinesia is a chronic condition with symptoms present from birth but there is significant variation both in clinical severity and the age at which the condition is diagnosed.^{9,15,16} There is usually a progressively greater impact on health from the second decade onwards, producing significant morbidity and life style restriction.¹⁷ In some cases of severe lung damage, heart-lung transplantation is required¹⁸ and in general patients greatly benefit from early diagnosis and management.^{16,19}

Primary ciliary dyskinesia is a phenotypically heterogeneous condition associated with a variety of ultrastructural abnormalities of the cilia and sperm flagella. These include absent dynein arms (approximately 70–80% of cases), absent radial spokes (5–10%), absent central pair microtubules, other rarer microtubular defects, and random ciliary orienta-

Key points

- Primary ciliary dyskinesia is an autosomal recessive disorder characterised by recurrent sinopulmonary infections, bronchiectasis, and subfertility, due to dysfunction of the cilia. Fifty percent of patients with primary ciliary dyskinesia have defects of laterality (situs inversus) and this association is known as Kartagener syndrome. Primary ciliary dyskinesia has an estimated incidence of 1 in 20 000 live births.
- To identify loci for this genetically heterogeneous condition, genome wide linkage scans and subsequent fine mapping were performed in two different isolated populations with distinct ciliary ultrastructural defects, from the Faroe Islands and the Druze community in northern Israel.
- A locus was mapped in seven families from the Faroe Islands to a 2.8 cM interval on chromosome 16p12.1-12.2, with a maximum lod score of 3.15, obtained using GENEHUNTER. A locus was mapped in three out of four Druze families from the Golan region of Israel to a 17 cM region on chromosome 15q13.1-15.1, with a maximum lod score of 3.2 at α (proportion of linked families)=0.7, using GENEHUNTER.
- This study provides further evidence of the genetic heterogeneity underlying primary ciliary dyskinesia and has established a framework to facilitate isolation of two genes for primary ciliary dyskinesia. Determining the molecular basis of primary ciliary dyskinesia will provide insight into the genetic control of cilia assembly and function and the pathway which determines the vertebrate left right axis.

tion.^{20–22} Genetic linkage analysis and mutational studies in patients with primary ciliary dyskinesia have shown that this disease is genetically heterogeneous, even within groups of families with the same specific ultrastructural defect.^{23–27} An unusual probable dominant inheritance pattern has also been reported for the disease.²⁸ Mutations in genes encoding two different axonemal outer dynein arm components (*DNAI1* and *DNAH5*) have been shown to cause primary ciliary dyskinesia in a number of patients with outer dynein arm defects.^{27,29} Defects in another dynein, *DNAH11*, have been

Abbreviation: PCD, primary ciliary dyskinesia

found in a patient with Kartagener syndrome and normal cilia ultrastructure.²⁶ The exact role of *DNAH11* in primary ciliary dyskinesia has yet to be elucidated. Two other genes for primary ciliary dyskinesia have been localised: *CILD2* to 19q,²³ and another locus to 15q24 (M P Witt, personal communication).

To identify loci for PCD, genome wide linkage scans and subsequent fine mapping were performed in two different isolated populations with distinct ciliary ultrastructural defects, from the Faroe Islands and the Druze community in northern Israel.

The Faroes comprise a small group of islands in the North Atlantic Ocean located near Iceland, Scotland, and Norway with a relatively young population of mixed Norwegian, Danish, and British ancestry. The islands were colonised at the same time as Iceland, around 1100 years ago and the population size remained small until rapid expansion in the 1800s. The current population size is estimated at 48 000 and has arisen predominantly by indigenous expansion.^{30–31} The Druze community, a small middle eastern religious sect, was established slightly later, in the eleventh century AD.³² Members live predominantly in defined geographical areas of southern Syria, southern Lebanon, and northern Israel and they remain isolated mainly for religious reasons. Both populations are also isolated for geographical and cultural reasons, in the Faroe Islands associated with limited immigration^{30–31} and in the Druze with a high level of consanguinity.³³

With relatively few founders, a limited population size, and recent expansion, the Faroes and Druze populations are suitable for genetic mapping of a heterogeneous recessive disease. This has been demonstrated in the Faroe Island population, in which enrichment of disease incidence associated with specific gene mutations due to founder effects has been shown for cystic fibrosis and glycogen storage disease IIIA.^{34–35} Similar findings have been reported for several conditions in the well studied Druze population including cystic fibrosis,³⁶ Krabbe disease³⁷ and mucopolysaccharidosis.³⁸ However the Druze population has not always proved to be genetically homogeneous.³⁹

We report here the identification of two new PCD loci in these genetic isolates, located on chromosomes 16p12.1–12.2 and 15q13.1–15.1 in the Faroe Island and Druze population respectively.

SUBJECTS AND METHODS

This study was carried out using the two family sets shown in fig 1. Informed consent was obtained in accordance with protocols approved by the University College London Hospital NHS Trust ethical committee. The diagnosis of affected subjects was made according to established clinical criteria⁹ supported by abnormal ciliary motility studies and electron microscopy of brushings or biopsy of nasal mucosa.

The Faroe Island resource consisted of seven families comprising 11 affected and 24 unaffected individuals (fig 1A). Clinical findings for some of the patients have been described previously.¹⁹ Only the affected child in UCL140 exhibited situs inversus. Electron microscopy defined an ultrastructural phenotype of absent outer dynein arms in Faroe patients (fig 2B). The patients were Faroese in origin, living on three of the islands only, except for the father in family UCL140, who was from Denmark. The families were treated as unrelated pedigrees in linkage analysis. There was unsupported verbal evidence for distant relatedness between families UCL96, UCL97, and UCL109, however no formal genealogical analysis has been possible to establish the precise relationships. There was one affected parent, the mother in family UCL98.

Four Druze Israeli families were studied comprising 7 affected and 22 unaffected individuals (Three are shown in fig 1B). The parents in three families, UCL122, UCL124, and UCL125, were first cousins, while the fourth family, UCL123, was non-consanguineous. In contrast to the Faroe Island population, Druze patients showed an unusually high incidence of situs inversus (six out of seven affected children). Electron microscopy defined an ultrastructural phenotype of partial absence of the inner dynein arms (fig 2C). Nasal brushings were processed for ultrastructural studies using established techniques⁴¹ and over 100 suitably oriented cross sections of cilia throughout the section were examined to confirm this structural defect. The four families were located in two neighbouring Druze villages comprising 7500 inhabitants, in the mountainous region of the Golan Heights. Families UCL122 and UCL124 were from one village and families UCL123 and UCL125 were from the other.

All of the patients with primary ciliary dyskinesia who were recognised within the two populations were ascertained and there is considerable population enrichment for primary ciliary dyskinesia in both the Faroe Island and Druze populations. The prevalence of primary ciliary dyskinesia in the Faroe Islands is around 1:4500 whilst the local prevalence amongst the Druze population studied is as high as 1:1000.

Genome wide scans of 10 cM density were performed in these two populations using four of the Faroe Island pedigrees (UCL96, 97, 98, and 109) and all four Druze pedigrees (UCL122, 123, 124, and 125). Genomic DNA was extracted from white blood cells using standard methodology.⁴² Over 350 hundred microsatellite markers from the Génethon map⁴³ were genotyped in each family by polymerase chain reaction and fluorescent based semi-automated methodology using methods previously described.^{24–44} Alleles were assigned using Genescan and Genotyper software (Applied Biosystems). Linkage analysis was performed under the assumption of autosomal recessive inheritance with a penetrance of 0.9, a disease allele frequency of 0.007 with equal allele frequencies (0.1) for each marker and a phenocopy rate of 0.00001. This disease allele frequency reflects the worldwide incidence of primary ciliary dyskinesia of 1:20 000. Analysis was also performed using the disease allele frequencies that reflected more closely the actual population frequencies we have determined for each population as described above: 0.015 for the Faroe Island families (incidence 1:4500) and 0.03 for the Druze families (incidence 1:1000). Multipoint analyses were performed using the GENEHUNTER program.

For subsequent fine mapping, six novel microsatellites were determined in the laboratory from the genomic sequence of BAC clones spanning the selected region. The primer pairs used to amplify these polymorphisms were: 5'-TGTTTCCTAGACGTGGTCAGC-3'/5'-ACTTGTACCTTTCAAACG-3' (16/4125), 5'-TGCAAACAGACTAGGACCAC-3'/5'-GGTCTCAAACCTCTGAGCTC-3' (16/10321), 5'-CACGCCTGGCTAGACTAATG-3'/5'-CTTTACCCAGTGACATACC-3' (15/14), 5'-GTCCCTATGCAACTTTCCAC-3'/5'-GAATGTGTTTCCCGCTC-3' (15/20), 5'-TCTCACCAGAACGAGAAAG-3'/5'-GGTGCCCGCTATAATCC-3' (15/23) and 5'-GAGTACCACCACTCAATCAAGG-3'/5'-CTCAGCAGCAGTTGTCAAG-3' (15/36).

Haplotypes were manually constructed using the most parsimonious allele configuration to minimise recombinants. Génethon marker order and genetic distances were determined from the deCODE Genetics high resolution genetic map.⁴⁰ Additional markers were positioned in the deCODE framework map based on their relative position within the human genome sequence available from the UCSC Genome Browser, April 2003 Build 33 sequence freeze.⁴⁵

Figure 1 Pedigrees consistent with linkage on chromosome 16p12.1-12.2 and 15q13.1-15.1. (A) Faroe Island and (B) Druze Israeli haplotypes. Filled symbols indicate individuals affected with primary ciliary dyskinesia, asterisks indicate patients with situs inversus, and a double line indicates first cousin marriage. Genetic markers used in the initial genome scan are shown in bold and the box indicates the minimum critical interval encompassing each locus. For each marker, alleles are coded numerically such that the same allele number correlates to the same allele size across families. The frameworks of microsatellite markers used were as follows with genetic distances indicated in Kosambi cM: D16S3046, 2.59; D16S3076, 0.003; D16S403, 0.1; D16S412, 0.5; D16S417, 1.3; UCL420, 0.36; 16/4125, 0.4; 16/10321, 0.16; D16S401, 0.01; D16S3133, 0.31; D16S319, 0.69; D16S3068, 0.99; D16S3131, 1.55; D16S3093, and D15S975, 2.09; D15S1002, 6.02; D15S1048, 1.57; D15S165, 1.99; D15S1031, 0.22; 15/14, 1.38; D15S1010, 1.19; 15/20, 0.87; D15S144, 0.57; D15S1007, 1.09; D15S1040, 0.96; 15/23, 0.92; D15S1232, 0.88; D15S971, 0.27; 15/36, 1.12; D15S118, 4.02; D15S1012. Genetic distances were taken from the DeCODE map³⁹ except for markers 16/4125, 16/10321, D16S319, 15/14, D15S1010, 15/20, 15/23, D15S1232 and 15/36. These were positioned relative to the DeCODE marker framework using Human Genome Project draft sequence information as described in the text.

Figure 2 Electron micrographs of cross sections of respiratory cilia from patients with primary ciliary dyskinesia. (A) Normal individual with 9+2 microtubule arrangement with intact outer and inner dynein arms. (B) Faroe Island individual with absent outer dynein arm defect. (C) Druze Israeli individual with partially absent inner dynein arm defect.

Physical distances were taken from this genomic sequence map.

RESULTS

A region consistent with linkage in the four Faroe Island families was identified on chromosome 16p12.1-13.1. No evidence for linkage at any of the known PCD loci was found. Fine mapping was undertaken in the entire seven family resource which included the three additional families UCL135, UCL139, and UCL140. Linkage analysis using GENEHUNTER was performed across a 9 cM region between markers *D16S3046* and *D16S3093*. This gave a maximum multipoint lod score of 3.15 between markers *D16S412* and *16/10321*. Using a disease allele frequency calculated from the actual recorded Faroe Island population disease incidence rather than worldwide incidence of primary ciliary dyskinesia, the maximum lod score obtained was 3.13. This is probably a conservative estimate of the true degree of linkage as the families were only analysed as unrelated pedigrees. Haplotype analysis indicated the key recombinant events defining the critical region on chromosome 16p12.1-12.2 (fig 1A). A paternal recombination in family UCL98 at *D16S403* defined the telomeric limit of the region. The centromeric limit was defined by a maternal recombination event in family UCL139 at *D16S3133*. The *D16S403*-*D16S3133* critical interval spans 2.8 cM which corresponds to a physical distance of 2.37 Mb.

Although no statistically significant evidence of a common disease associated haplotype amongst the families could be proven, three markers in the *D16S403*-*D16S3133* interval did show a suggestion of linkage disequilibrium with a higher frequency of certain alleles on disease chromosomes compared to control chromosomes. The control data were taken from genotypes on the families' obligate normal chromosomes and on chromosomes from a small set of unrelated Faroe control individuals. The three markers were *16/4125*, *D16S401*, and *D16S3133*, with $p < 0.1$ for all three using Fisher's exact test. At *16/4125* allele 2 was present on 3/15 (20%) of disease and 1/25 (4%) of control chromosomes; *D16S401* allele 2 was present on 6/15 (40%) of disease and 7/25 (28%) of control chromosomes; and *D16S3133* allele 1 was present on 8/15 (53%) disease and 3/13 (23%) of control chromosomes. All other markers in the entire *D16S3046*-*D16S3093* interval were non-significant. It was also noted that the affected child in family UCL98 is homozygous for the haplotype 3-2-2 at markers *16/4125*-*16/10321*-*D16S401*.

Data from one additional Faroe Island pedigree were not included in the present study. Exclusion from the chromosome 16 locus was indicated in this family suggesting the possibility of locus heterogeneity amongst Faroe Islanders. However clinical data on the individual who appears to be

recombinant across the region if affected remains incomplete and the affection status of this individual remains uncertain at present.

Three out of four of the Druze families were consanguineous and a homozygosity mapping approach⁴⁶ was used. Genome scan markers were scored for homozygosity in the affected individuals in families UCL122, UCL124, UCL125, and for consistency of linkage in the non-consanguineous family UCL123. Four regions of excess homozygosity were identified on chromosomes 1q32, 3p25, 5q33, and 15q13. Fine mapping using additional markers at each region resulted in exclusion of all regions except that on chromosome 15q13. Linkage analysis using GENEHUNTER across a 25 cM region between markers *D15S975* and *D15S1012* gave a maximum multipoint lod score between markers *D15S1031* and *D15S118* of 3.2 allowing for heterogeneity, at α (proportion of linked families) = 0.73 which suggested that three out of four families were linked. Using a disease allele frequency calculated from the actual recorded Druze population disease incidence rather than worldwide incidence of primary ciliary dyskinesia, the maximum lod score obtained dropped to 3.0. Haplotype analysis confirmed linkage in families UCL122, UCL123, and UCL125, but not in UCL124. No evidence for linkage of family UCL124 to any of the known PCD loci was found. The key recombination events defining the critical region were determined (fig 1B). The centromeric and telomeric limits of the region were defined by loss of homozygosity at *D15S1048* in the affected child in UCL125 and a maternal recombination in family UCL122 at *D15S1012* respectively. The *D15S1048*-*D15S1012* critical interval on chromosome 15q13.1-15.1 spans a region of 17 cM, corresponding to a physical distance of 9.1 Mb. Interestingly the non-consanguineous family UCL123 was homozygous by descent for alleles at the markers *D15S1031*, *15/14*, *D15S1010*, *15/23*, and *D15S1232*, identifying these as regions of potential interest if the families harbour a single ancestral mutation. However the significance is reduced since there was no evidence of allele sharing amongst affected Druze patients.

DISCUSSION

These results provide statistically significant support for loci for primary ciliary dyskinesia on chromosomes 16p12.1-12.2 and 15q13.1-15.1. Since primary ciliary dyskinesia is a genetically and clinically heterogeneous disorder the selection of patients with an identical ultrastructural phenotype and families from isolated populations should minimise the risk of genetic heterogeneity. The incidence of inbreeding is often high in these populations which may allow the application of homozygosity or linkage disequilibrium mapping to identify and refine the disease gene localisation. This is a powerful approach⁴⁶ and has proved successful in mapping many autosomal recessive diseases including

primary ciliary dyskinesia, even in the presence of heterogeneity.^{24 47 48} This study uses PCD family groups from two genetically isolated populations from the Faroe Islands and the Golan Heights Druze community, both of which were founded and have expanded relatively recently. There is significant enrichment for primary ciliary dyskinesia in both these populations presumably due to isolation and inbreeding, the incidence being around 1:4500 in the Faroe Islands and 1:1000 in the Druze population studied.

In both populations the initial assumption was that the existence of single ancestral Faroe Island or Druze mutation would account for all the patients in each group. However, in the present study such linkage disequilibrium has not been detected. At the Faroes locus no common haplotype was observed among the affected subjects even amongst families UCL96, UCL97, and UCL109, who may be interrelated, and the allele sharing observed was not statistically significant. Identification of linkage disequilibrium by additional marker typing at both loci would be useful to further refine the critical interval and pinpoint the localisation of the disease gene.

The extent of linkage disequilibrium encompassing a disease gene allele is dependent of course on a number of factors including natural selection and physical features such as the local recombination and gene conversion rate. Population scale effects include the population size, demographic and admixture history. A large population under mutation drift equilibrium displays low levels of linkage disequilibrium while high linkage disequilibrium correlates with a small population due to genetic drift. If the population is reduced, then allelic diversity is lowered and genetic drift is increased. Simulation studies on human populations predicts that slow early growth, such as that which occurred in the Faroes population, can be a key factor in increasing the extent of linkage disequilibrium in an isolated population.^{49 50} The age of the disease and marker alleles can be regarded as one of the most important considerations; the exact timing of the primary ciliary dyskinesia gene mutation in terms of when it occurred within the population will influence the extent to which it has expanded in the population. If the ancestral mutation is very ancient the region of linkage disequilibrium may have been eroded by ancient recombinations leaving it extremely small.

We have demonstrated locus heterogeneity in the PCD Druze families since only three of the four families are linked to the 15q locus. Moreover the lack of allele sharing suggests allelic heterogeneity. The intense inbreeding within this community could allow different mutations on different haplotypes of a disease gene to expand within the population giving rise to allelic heterogeneity. It has been suggested that multiple mutations in a single specific gene in a small geographic area and in inbred families may in fact be a common phenomenon.^{51 52} Such allelic heterogeneity has been well described in previous molecular genetic studies in the Druze population. Three different iduronidase mutations were found to cause Hurler syndrome in Druze patients from the Galilee region of Israel⁵³ and five different mutations in the arylsulfatase A gene causing metachromatic leucodystrophy, occurring on at least three different haplotypes, were reported in the same region.⁵⁴ Two different mutations and three different genotypes were noted in a small Druze kindred with Wilson's disease.⁵⁵

Both critical regions on chromosome 16p12.1-12.2 and 15q13.1-15.1 contain no obvious candidate genes based on known or predicted function or association with axonemal function. The disease genes may therefore encode proteins with a novel structural or regulatory role in cilia or flagella, associated with distinct outer (Faroe Island) and inner

(Druze) dynein arm functions. From published reports and expressed sequence tag, protein and gene prediction annotation derived from the UCSC Genome Browser, RefSeq, NCBI Map Viewer, Ensembl transcript and human cDNA collections,^{45 56} the chromosome 16p12.1-12.2 critical region contains 15 distinct genes verified with strong experimental support, and three predicted genes. Using the same criteria the chromosome 15q13.1-15.1 critical region contains 25 well supported genes and 15 predicted genes.

With the identification of two new loci for primary ciliary dyskinesia, the two candidate intervals defined on chromosomes 16p12.1-12.2 and 15q13.1-15.1 provide a framework for the isolation of the putative genes causing primary ciliary dyskinesia. The evolutionary conservation of cilia and flagella structure and function and of the genes encoding axonemal proteins has previously been used to facilitate isolation of human PCD genes.^{26 27 29} Along with advances in the human genome project there has been huge progress with the genome projects for the flagellated PCD model organisms *Chlamydomonas* and *Trypanosoma*.⁵⁷⁻⁵⁹ Their genome sequence information and annotation is publicly available (<http://genome.jgi-psf.org/chlre1/chlre1.home.html>, <http://parsun1.path.cam.ac.uk/overview.htm>) and it is now possible to incorporate cross species comparative genomics into the bioinformatics based prioritisation of PCD candidate genes. Technical advances in genetic manipulation of these model organisms are also of great potential value, for example for screening for a flagellar phenotype in mutant *Chlamydomonas* and *Trypanosoma* strains in which the expression of homologues of PCD candidate genes has been ablated by RNA interference.⁶⁰⁻⁶²

Another postgenomic approach applied to the study of cilia structure and function is also likely to prove useful in the search candidate genes for primary ciliary dyskinesia. Ostrowski and colleagues recently reported results from the first proteomic analysis of the human ciliary axoneme, aimed at characterising all the constitutive protein components.⁶³ In this study one and two dimensional gel electrophoresis of cilia from human bronchial epithelial biopsy produced a map of over 200 putative axonemal proteins, yielding many potentially novel components of this complex organelle. Our own bio-informatic analysis has indicated that none of the available protein sequences from this study correspond to gene products predicted to map to either the 16p12.1-12.2 or the 15q13.1-15.1 loci. Ciliary actin identified in the proteomic set does have domain similarity to both a cardiac specific and a skeletal muscle specific actin isoform located in the critical region on chromosome 15 but there does not appear to be a functional correlation. Proteomic studies such as this have enormous promise and are highly appropriate for analysis of the cilium. Techniques for more direct analysis of complex protein mixtures using methods based on mass spectrometry and the development of protein "chips" are actively evolving fields which will further advance this approach.⁶⁴

In conclusion, this study reinforces the value of isolated human populations in gene mapping of heterogeneous disorders. Determining the molecular basis of primary ciliary dyskinesia will provide insight into the genetic control of cilia assembly and function and the pathway which determines the vertebrate left-right axis.

ACKNOWLEDGEMENTS

We are grateful to the populations of the Faroe Islands and Israel Golan Heights and to all the individuals who participated in this study. We thank Drs Michael Dunn, Amanda Walne, Martin Gray and Ms Laure Boudery for clinical ascertainment and technical support. We thank Drs Christopher O'Callaghan and Wendy Stannard for the electron micrograph of a normal axoneme.

Authors' affiliations

D Jeganathan, R Chodhari, M Meeks, R M Gardiner, E M K Chung, H M Mitchison, Department of Paediatrics and Child Health, Royal Free and University College Medical School, University College London, UK
O Færoe, Landssjúkrahúsið, Department of Paediatrics, Tórshavn, Faroe Island

D Smyth, MRC Geneservice, Babraham Biocubator, Babraham, Cambridge, UK

K Nielsen, Pulmonary Service, Department of Paediatrics, Rigshospitalet, National University Hospital, Copenhagen, Denmark

I Amirav, A S Luder, Paediatric Pulmonary Unit, Sieff Hospital, Safed, Israel

H Bisgaard, COPSAC Clinical Research Unit, Copenhagen University Hospital, Gentofte, Copenhagen, Denmark

This work was supported by the Wellcome Trust.

*Both authors have contributed equally to the work.

†Present address: Neonatal Unit, Leicester General Hospital, Gwendolen Road, Leicester.

Competing interests: none declared.

Correspondence to: Dr Hannah Mitchison, Department of Paediatrics and Child Health, Royal Free and University College Medical School, Rayne Building, 5 University Street, London WC1E 6JJ; hmitchis@ucl.ac.uk

Received 8 September 2003

Revised version received 24 October 2003

Accepted 20 November 2003

REFERENCES

- Afzelius BA. A human syndrome caused by immotile cilia. *Science* 1976;193:317–9.
- Sleigh MA, Blake JR, Liron N. The propulsion of mucus by cilia. *Am Rev Respir Dis* 1988;137:726–41.
- Katz DF, Berger SA. Flagellar propulsion of human sperm in cervical mucus. *Biorheology* 1980;17:169–75.
- Piperno G, Huang B, Luck DJ. Two-dimensional analysis of flagellar proteins from wild-type and paralyzed mutants of *Chlamydomonas reinhardtii*. *Proc Natl Acad Sci U S A* 1977;74:1600–4.
- Dutcher SK. Flagellar assembly in two hundred and fifty easy-to-follow steps. *Trends Genet* 1995;11:398–404.
- Fawcett DW, Porter KR. A study of the fine structure of ciliated epithelia. *J Morphol* 1954;94:221–64.
- Porter ME, Sale WS. The 9+2 axoneme anchors multiple inner arm dyneins and a network of kinases and phosphatases that control motility. *J Cell Biol* 2000;151:F37–42.
- King SM. Organization and regulation of the dynein microtubule motor. *Cell Biol Int* 2003;27:213–5.
- Meeks M, Bush A. Primary ciliary dyskinesia (PCD). *Pediatr Pulmonol* 2000;29:307–16.
- Supp DM, Potter SS, Brueckner M. Molecular motors: the driving force behind mammalian left-right development. *Trends Cell Biol* 2000;10:41–5.
- Schneider H, Brueckner M. Of mice and men: dissecting the genetic pathway that controls left-right asymmetry in mice and humans. *Am J Med Genet* 2000;97:258–70.
- McGrath J, Somlo S, Makova S, Tian X, Brueckner M. Two populations of node monocilia initiate left-right asymmetry in the mouse. *Cell* 2003;114:61–73.
- Bush A, O'Callaghan C. Primary ciliary dyskinesia. *Arch Dis Child* 2002;87:363–5, discussion 363–5.
- Rutland J, Griffin W, Cole P. Nasal brushing and measurement of ciliary beat frequency. An in vitro method for evaluating pharmacologic effects on human cilia. *Chest* 1981;80(suppl 6):865–7.
- Bush A, Cole P, Hariri M, Mackay I, Phillips G, O'Callaghan C, Wilson R, Warner JO. Primary ciliary dyskinesia: diagnosis and standards of care. *Eur Respir J* 1998;12:982–8.
- Coren ME, Meeks M, Morrison I, Buchdahl RM, Bush A. Primary ciliary dyskinesia: age at diagnosis and symptom history. *Acta Paediatr* 2002;91:667–9.
- McManus IC, Mitchison HM, Chung EMJ, Stubbings GF, Martin N. Primary Ciliary Dyskinesia (Siewert's/Kartagener's Syndrome): respiratory symptoms and psycho-social impact. *BMC Pulm Med* 2003;3:4.
- Cowan MJ, Gladwin MT, Shelhamer JH. Disorders of ciliary motility. *Am J Med Sci* 2001;321:3–10.
- Ellerman A, Bisgaard H. Longitudinal study of lung function in a cohort of primary ciliary dyskinesia. *Eur Respir J* 1997;10:2376–9.
- Palmlad J, Mossberg B, Afzelius BA. Ultrastructural, cellular, and clinical features of the immotile-cilia syndrome. *Annu Rev Med* 1984;35:481–92.
- Greenstone M, Rutman A, Dewar A, Mackay I, Cole PJ. Primary ciliary dyskinesia: cytological and clinical features. *Q J Med* 1988;67:405–23.
- De longh RU, Rutland J. Ciliary defects in healthy subjects, bronchiectasis, and primary ciliary dyskinesia. *Am J Respir Crit Care Med* 1995;151:1559–67.
- Blouin JL, Meeks M, Radhakrishna U, Sainsbury A, Gehring C, Sail GD, Bartoloni L, Dombi V, O'Rawe A, Walne A, Chung E, Afzelius BA, Armengot M, Jorissen M, Schidlow DV, van Maldergem L, Walt H, Gardiner RM, Probst D, Guerne PA, Delozier-Blanchet CD, Antonarakis SE. Primary ciliary dyskinesia: a genome-wide linkage analysis reveals extensive locus heterogeneity. *Eur J Hum Genet* 2000;8:109–18.
- Meeks M, Walne A, Spiden S, Simpson H, Mussaffi-Georgy H, Hamam HD, Fehaid EL, Cheehab M, Al-Dabbagh M, Polak-Charcon S, Blau H, O'Rawe A, Mitchison HM, Gardiner RM, Chung E. A locus for primary ciliary dyskinesia maps to chromosome 19q. *J Med Genet* 2000;37:241–4.
- Guichard C, Harricane MC, Lafitte JJ, Godard P, Zaegel M, Tack V, Lalau G, Bouvagnet P. Axonemal dynein intermediate-chain gene (DNAI1) mutations result in situs inversus and primary ciliary dyskinesia (Kartagener syndrome). *Am J Hum Genet* 2001;68:1030–5.
- Bartoloni L, Blouin JL, Pan Y, Gehrig C, Maiti AK, Scamuffa N, Rossier C, Jorissen M, Armengot M, Meeks M, Mitchison HM, Chung EM, Delozier-Blanchet CD, Craigen WJ, Antonarakis SE. Mutations in the DNAH11 (axonemal heavy chain dynein type 11) gene cause one form of situs inversus totalis and most likely primary ciliary dyskinesia. *Proc Natl Acad Sci U S A* 2002;99:10282–6.
- Olbrich H, Haffner K, Kispert A, Volk A, Volz A, Sasmaz G, Reinhardt R, Hennig S, Lehrach H, Konietzko N, Zariwala M, Noone PG, Knowles M, Mitchison HM, Meeks M, Chung EM, Hildebrandt F, Sudbrak R, Omran H. Mutations in DNAH5 cause primary ciliary dyskinesia and randomization of left-right asymmetry. *Nat Genet* 2002;30:143–4.
- Narayan D, Krishnan SN, Upender M, Ravikumar TS, Mahoney MJ, Dolan TF Jr, Teebi AS, Haddad GG. Unusual inheritance of primary ciliary dyskinesia (Kartagener's syndrome). *J Med Genet* 1994;31:493–6.
- Pennarun G, Escudier E, Chapelin C, Bridoux AM, Cacheux V, Roger G, Clement A, Goossens M, Amselem S, Duriez B. Loss-of-function mutations in a human gene related to *Chlamydomonas reinhardtii* dynein IC78 result in primary ciliary dyskinesia. *Am J Hum Genet* 1999;65:1508–19.
- West JF. *Faroe: the emergence of a nation*. London: C Hurst, 1972.
- Jorgensen TH, Degn B, Wang AG, Vang M, Gurling H, Kalsi G, McQuillin A, Kruse TA, Mors O, Ewald H. Linkage disequilibrium and demographic history of the isolated population of the Faroe Islands. *Eur J Hum Genet* 2002;10:381–7.
- Swayd SS. *The Druzes: an annotated bibliography*. Kirkland, WA: ISES Publications, 1988.
- Vardi-Saliternik R, Friedlander Y, Cohen T. Consanguinity in a population sample of Israeli Muslim Arabs, Christian Arabs and Druze. *Ann Hum Biol* 2002;29:422–31.
- Schwartz M, Sorensen N, Brandt NJ, Hogdall E, Holm T. High incidence of cystic fibrosis on the Faroe Islands: a molecular and genealogical study. *Hum Genet* 1995;95:703–6.
- Santer R, Kinner M, Steuerwald U, Kjaergaard S, Skovby F, Simonsen H, Shaiu WL, Chen YT, Schneppenheim R, Schaub J. Molecular genetic basis and prevalence of glycogen storage disease type IIIA in the Faroe Islands. *Eur J Hum Genet* 2001;9:388–91.
- Lerer I, Laufer-Cahana A, Rivlin JR, Augarten A, Abeliovich D. A large deletion mutation in the CFTR gene (3120+1Kbdel8.6Kb): a founder mutation in the Palestinian Arabs. Mutation in brief no 231. *Online. Hum Mutat* 1999;13:337.
- Rafi MA, Luzi P, Zlotogora J, Wenger DA. Two different mutations are responsible for Krabbe disease in the Druze and Moslem Arab populations in Israel. *Hum Genet* 1996;97:304–8.
- Raas-Rothschild A, Cormier-Daire V, Bao M, Genin E, Salomon R, Brewer K, Zeigler M, Mandel H, Toth S, Roe B, Munnich A, Canfield WM. Molecular basis of variant pseudo-hurler polydystrophy (mucopolidiosis IIIC). *J Clin Invest* 2000;105:673–81.
- Adato A, Roskin L, Petit C, Bonne-Tamir B. Deafness heterogeneity in a Druze isolate from the Middle East: novel OTOF and PDS mutations, low prevalence of GJB2 35delG mutation and indication for a new DFNB locus. *Eur J Hum Genet* 2000;8:437–42.
- Kong A, Gudbjartsson DF, Sainz J, Jonsson GM, Gudjonsson SA, Richardsson B, Sigurdardottir S, Barnard J, Hallbeck B, Masson G, Shlien A, Palsson ST, Frigge ML, Thorgeirsson TE, Gulcher JR, Stefansson K. A high-resolution recombination map of the human genome. *Nat Genet* 2002;31:241–7.
- Rutland J, Cole PJ. Non-invasive sampling of nasal cilia for measurement of beat frequency and study of ultrastructure. *Lancet* 1980;ii(8194):564–5.
- Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. *Nucleic Acids Res* 1988;16:1215.
- Dib C, Faure S, Fizames C, Samson D, Drouot N, Vignal A, Millasseau P, Marc S, Hazan J, Seboun E, Lathrop M, Gyapay G, Morissette J, Weissenbach J. A comprehensive genetic map of the human genome based on 5264 microsatellites. *Nature* 1996;380:152–4.
- Vulliamy T, Marrone A, Goldman F, Dearlove A, Bessler M, Mason PJ, Dokal I. The RNA component of telomerase is mutated in autosomal dominant dyskeratosis congenita. *Nature* 2001;413:432–5.
- Kent WJ, Sugnet CW, Furey TS, Roskin KM, Pringle TH, Zahler AM, Haussler D. The human genome browser at UCSC. *Genome Res* 2002;12:996–1006.
- Lander ES, Botstein D. Homozygosity mapping: a way to map human recessive traits with the DNA of inbred children. *Science* 1987;236:1567–70.
- Strautnieks SS, Thompson RJ, Hanukoglu A, Dillon MJ, Hanukoglu I, Kuhnle U, Seckl J, Gardiner RM, Chung E. Localisation of pseudohypoadosteronism genes to chromosome 16p12.2-13.11 and 12p13.1-pter by homozygosity mapping. *Hum Mol Genet* 1996;5:293–9.

- 48 **Omran H**, Haffner K, Volkel A, Kuehr J, Ketelsen UP, Ross UH, Konietzko N, Wienker T, Brandis M, Hildebrandt F. Homozygosity mapping of a gene locus for primary ciliary dyskinesia on chromosome 5p and identification of the heavy dynein chain DNAH5 as a candidate gene. *Am J Respir Cell Mol Biol* 2000;**23**:696–702.
- 49 **Slatkin M**. Linkage disequilibrium in growing and stable populations. *Genetics* 1994;**137**:331–6.
- 50 **Huttley GA**, Smith MW, Carrington M, O'Brien SJ. A scan for linkage disequilibrium across the human genome. *Genetics* 1999;**152**:1711–22.
- 51 **Zlotogora J**, Gieselmann V, Bach G. Multiple mutations in a specific gene in a small geographic area: a common phenomenon? *Am J Hum Genet* 1996;**58**:241–3.
- 52 **Carraquillo MM**, Zlotogora J, Barges S, Chakravarti A. Two different connexin 26 mutations in an inbred kindred segregating non-syndromic recessive deafness: implications for genetic studies in isolated populations. *Hum Mol Genet* 1997;**6**:2163–72.
- 53 **Bach G**, Moskowitz SM, Tieu PT, Matynia A, Neufeld EF. Molecular analysis of Hurler syndrome in Druze and Muslim Arab patients in Israel: multiple allelic mutations of the IDUA gene in a small geographic area. *Am J Hum Genet* 1993;**53**:330–8.
- 54 **Heinisch U**, Zlotogora J, Kafert S, Gieselmann V. Multiple mutations are responsible for the high frequency of metachromatic leukodystrophy in a small geographic area. *Am J Hum Genet* 1995;**56**:51–7.
- 55 **Kalinsky H**, Funes A, Zeldin A, Pel-Or Y, Korostishevsky M, Gershoni-Baruch R, Farrer LA, Bonne-Tamir B. Novel ATP7B mutations causing Wilson disease in several Israeli ethnic groups. *Hum Mutat* 1998;**11**:145–51.
- 56 **Hubbard T**, Barker D, Birney E, Cameron G, Chen Y, Clark L, Cox T, Cuff J, Curwen V, Down T, Durbin R, Eyrae E, Gilbert J, Hammond M, Huminecki L, Kasprzyk A, Lehtvaslao H, Lijnzaad P, Melsopp C, Mongin E, Pettett R, Pocock M, Potter S, Rust A, Schmidt E, Searle S, Slater G, Smith J, Spooner W, Stabenau A, Stalker J, Stupka E, Ureta-Vidal A, Vastrik I, Clamp M. The Ensembl genome database project. *Nucleic Acids Res* 2002;**30**:38–41.
- 57 **El Zein L**, Omran H, Bouvagnet P. Lateralization defects and ciliary dyskinesia: lessons from algae. *Trends Genet* 2003;**19**:162–7.
- 58 **Shrager J**, Hauser C, Chang CW, Harris EH, Davies J, McDermott J, Tamse R, Zhang Z, Grossman AR. Chlamydomonas reinhardtii genome project. A guide to the generation and use of the cDNA information. *Plant Physiol* 2003;**131**:401–8.
- 59 **Vaughan S**, Gull K. The trypanosome flagellum. *J Cell Sci* 2003;**116**:757–9.
- 60 **Sineschekov OA**, Jung KH, Spudich JL. Two rhodopsins mediate phototaxis to low- and high-intensity light in Chlamydomonas reinhardtii. *Proc Natl Acad Sci U S A* 2002;**99**:8689–94.
- 61 **Koblenz B**, Schoppmeier J, Grunow A, Lechtreck KF. Centrin deficiency in Chlamydomonas causes defects in basal body replication, segregation and maturation. *J Cell Sci* 2003;**116**:2635–46.
- 62 **McKean PG**, Baines A, Vaughan S, Gull K. Gamma-tubulin functions in the nucleation of a discrete subset of microtubules in the eukaryotic flagellum. *Curr Biol* 2003;**13**:598–602.
- 63 **Ostrowski LE**, Blackburn K, Radde KM, Moyer MB, Schlatter DM, Moseley A, Boucher RC. A proteomic analysis of human cilia: identification of novel components. *Mol Cell Proteomics* 2002;**1**:451–65.
- 64 **Pandey A**, Mann M. Proteomics to study genes and genomes. *Nature* 2000;**405**:837–46.

CORRECTION

doi: 10.1136/jmg.2003.014761corr1

Venturin M, Guarnieri P, Nattaci F, *et al.* Mental retardation and cardiovascular malformations in NF1 microdeleted patients point to candidate genes in 17q11.2 (*J Med Genet* 2003;**41**:35–41). We would like to offer our sincere apologies to the authors of this paper for a number of errors that were introduced regarding the incorrect use of the term “learning disability”. The instances of “learning disability” in the Key points box, and in Tables 1 and 2 should be “mental retardation”. These errors are much regretted and the corrected versions are shown here.

Table 1 Presence of specific clinical signs in 92 NF1 microdeleted patients v NF1 patients according to published reports

Clinical signs	NF1 microdeleted patients			NF1 patients	
	Total evaluable	Total affected	%	%	Discordance* (χ^2 value)
Plexiform neurofibroma	88	25	28	25 to 30	No (0.36 to 0.13)
Macrocephaly	63	20	32	40 to 50	No (1.6 to 6.48)
Facial dysmorphism†	88	69	78	5 to 15	Yes (1065.8 to 264.6)
Hypertelorism	64	27	42	15	Yes (48.60)
Mental retardation	63	36	57	4 to 8	Yes (702 to 300.1)
Seizures	56	5	9	3.8 to 6	No (7.11 to 1.5)
Cardiovascular malformations‡	61	11	18	2.1	Yes (120.39)
Deafness	82	2	2	5.3	No (2.05)
Scoliosis	60	9	15	10 to 30	No (2.5 to 7.5)
Pectus excavatum-carinatum	58	10	17	20	No (0.45)

*The discordant values between the two groups of patients and the relative clinical signs are given in bold.

†Including the following signs, each observed in at least one patient: coarse face, flat occiput/brachycephaly, facial asymmetry, prominent forehead, frontal bossing, ptosis, downslanting deep set eyes, eversion of the lateral eyelid, epicanthic folds, strabismus, large nose, prominent nose, high nasal bridge, broad nasal bridge, broad nose, bulbous nasal tip, large ears, low set ears, malar hypoplasia, wide philtrum, prominent philtrum, small mouth, thick lips, micrognathia, small pointed chin, low posterior hairline.

‡Including: atrial septal defect, ventricular septal defect, patent ductus arteriosus, pulmonary stenosis, dilated aortic valve, hypertrophic cardiomyopathy, mitral valve prolapse.

Table 2 Clinical features of the 14 newly described patients carrying NF1 microdeletion characterised by refined fluorescent in situ hybridisation (FISH) analysis

Patient	Age (years)	Sex	Deletion type	Clinical signs				
				Growth defects	Dysmorphic	Mental retardation	Cardiovascular malformation	Other features
119	4	M	REP	No	No	No	–	
118	5	M	cen-REP	No	No	No	–	Optic glioma, seizures
93	6	M	REP	90th centile, macrocephaly	Yes*	No	HCM	Broad neck, 3 NFs
65	6	M	REP	Height 3rd centile, microcephaly 2nd centile	Yes†	IQ48	VSD (upper part)	Small hands/feet, short fingers
116	6	M	REP	Short stature 10th centile	Yes‡	IQ54	Mitral insufficiency	MCLS, kyphoscoliosis, pectus excavatum, genu valgus, pes planus, umbilical hernia
72	7	M	REP	No	Yes§	IQ50		Small hands/feet, short fingers
76	8	F	REP	No	Yes¶	No	–	–
94	8	F	REP	No	Yes**	No	–	–
75	9	F	REP	No	Yes††	No	–	–
85	11	M	REP	No	No	IQ77	–	MCLS
7	11	M	REP	No	Yes‡‡	Speech impairment	–	MCLS, amblyopia, thalamic hamartoma
82	23	F	REP	Short stature	No	No	–	Hearing impairment, Noonan-like
77	U	F	REP	Overgrowth >97th centile	Yes§§	Speech impairment, LD	–	NFs, required special education, short and broad fingers and toes
78	U	F	REP	–	Yes¶¶	Speech impairment	–	Delayed motor development, short and broad feet, fifth finger clinodactyly

*Hypertelorism, epicanthic folds, low set ears, low posterior hairline.

†Hypertelorism, downslanting eye, strabismus, large and prominent nose with high and broad bridge, bulbous nasal tip, large and low set ears, malar hypoplasia, wide and prominent philtrum, small mouth, small pointed chin.

‡Hypertelorism, long philtrum, broad nose.

§Prominent forehead, hypertelorism, ptosis (O.DX), downslanting eyes; strabismus, large and prominent nose with high and broad bridge and bulbous nasal tip, large and low set ears, wide and prominent philtrum, low posterior hairline.

¶Coarse face, hypertelorism.

**††Epicanthic folds.

‡‡Hypertelorism, broad and wild nasal bridge, broad nasal tip.

§§Simple facial features.

¶¶Epicanthic folds, bulbous nose, narrow high palate, low forehead.

cen-REP, deletion extending centromerically to REP-P; CVM, cardiovascular malformations; F, female; HCM, hypertrophic cardiomyopathy; LD, learning disabilities; M, male; MCLS, multiple café-au-lait spots; NF, neurofibroma; REP, NF1 repeat mediated deletion; U, unknown; VSD, ventricular septal defect.

Key points

- NF1 microdeletion syndrome is determined by haploinsufficiency of the NF1 gene and its flanking regions; NF1 microdeleted patients show a more severe phenotype than observed in classical NF1 patients.
- The aim of this study was to verify the presence of specific clinical signs of NF1 microdeletion, by combining clinical and genetic evidence from 92 deleted patients, 14 newly characterised and 78 already published.
- Statistical analysis, done by comparing the frequency of 10 clinical signs between NF1 microdeleted patients and the whole NF1 population, showed that the most common extra-NF1 clinical signs in microdeleted patients were mental retardation, cardiovascular malformations, and dysmorphisms.
- Using bioinformatic tools, the deletion gene content of 44 genetically and clinically characterised patients was established. It is proposed that haploinsufficiency of OMG and/or CDK5R1 genes may be implicated in mental retardation. In relation to cardiovascular malformations, only JAZ1 and CEN2A2 can be considered as plausible candidate genes.
- When present in an NF1 patient, dysmorphisms, cardiac anomalies, and mental retardation are signs indicating NF1 microdeletion.

CORRECTION

doi: 10.1136/jmg.2003.008433corr

Owing to the change over of typesetters at the BMJ Publishing Group Ltd last year, we would like to apologise for an error that was published in the paper by Baser *et al* (*J Med Genet* 2003;40:758–760). In Table 2 the headings 'Classical NF2' and 'Somatic mosaic' should be indented as they are subsections of the heading 'Nonsense or frame-shift'.